1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny...
-
Upload
merilyn-russell -
Category
Documents
-
view
215 -
download
1
Transcript of 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny...
![Page 1: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/1.jpg)
1
Health and Disease in Populations 2002Week 9 – 2/5/02
Randomised controlled trials 2
Dr Jenny Kurinczuk
![Page 2: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/2.jpg)
2
Lecture objectives
You should be able to:
1. Describe suitable outcome measures for trials
2. Discuss how to deal with losses to follow-up and non-compliance
![Page 3: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/3.jpg)
3
Lecture objectives
3. Differentiate between explanatory and pragmatic trials and be able to explain the meaning of the term ‘analysis by intention-to-treat’
4. Explain the problems associated with non-randomised trials and the use of historical controls
![Page 4: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/4.jpg)
4
Recap - the basic steps involved• RCTs are experimental studies
• In contrast to observational studies the researcher has control over who receives what exposure -the exposure is the treatment A or B
• Is new treatment A better than old treatment B ?
![Page 5: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/5.jpg)
5
Recap - the basic steps involved
• Define the disease (inclusions & exclusions)
• Define the treatments, A & B(issue of placebos & placebo effect)
• Find a suitable group of patients• Invite them and consent them• Randomly allocate them to A or B
(double blind - Dr & patient both blind)• Follow-up, define and compare the
outcomes in the two groups
![Page 6: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/6.jpg)
6
Objective 1: Suitable ‘outcome’ measures for trials
• Evaluation of patient progress needs to be:
– Objective– Accurate – Consistent – reproducible– Blind to treatment allocation– Evaluated against a pre-defined end
point
![Page 7: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/7.jpg)
7
Outcome measures for trials
• Choice of primary outcome measure– eg cancer treatment:
• Survival time• Reduction in tumour size• Duration of tumour response• Quality of life
• Choose one of these at the outset• May wish to measure the others as
secondary end-points together with side effects
![Page 8: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/8.jpg)
8
Outcome measures for trials
• Method of assessment (generally more rigorous than usual clinical practice) involves:
– Baseline assessment & recording– Monitoring of progress and side-
effects during the treatment period– Assessment of the primary outcome
(secondary and side-effects)
![Page 9: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/9.jpg)
9
Outcome measures for trials
• Baseline assessment & recording:– Clinical condition using a predefined
‘measurement’ protocol eg: • sitting BP measured using calibrated automated
machine• Size/area of wound• Pain measured using validate scale
– Personal characteristics (eg age, sex)– Relevant medical history – Other test results possibly eg ECG
![Page 10: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/10.jpg)
10
Outcome measures for trials
• Assessment of the primary outcome (secondary and side-effects):
– Pre-defined measure using predefined ‘measurement’ protocol:• sitting BP measured using calibrated automated
machine• Size/area of wound• Pain measured using validate scale
– Define when and how often to measure and at what point the end of the trial is reached
![Page 11: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/11.jpg)
11
Objective 2: Dealing with losses to follow-up and non-compliance
• So, assume we have randomised the patients to the two treatments and given them the drugs (tablets)
• We may see them at intervals to monitor progress and at the pre-defined end-point to determine the outcome
![Page 12: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/12.jpg)
12
Losses to follow-up and non-compliance
Losses to follow-up:• Not everyone continues in the
trial– Clinical condition requires removal
from the trial (this is appropriate)– Patient opts out (this is unfortunate)
![Page 13: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/13.jpg)
13
Losses to follow-up and non-compliance Losses to follow-up:• Difficult to minimise
– Make the follow-up for the patients practical and not too onerous
– Make the trial requirements clear at the outset (prior to consent)
– Avoid bribery and coercion– Avoid direct payment but pay travel
& out-of-pocket expenses
![Page 14: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/14.jpg)
14
Losses to follow-up and non-compliance
• Non-compliance:– Not everyone takes the treatment either
properly or at all
• Difficult to minimise:- Provide clear written instructions
- Tablet count– Monitor with blood or urine tests (if
possible)
![Page 15: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/15.jpg)
15
Losses to follow-up and non-compliance
Need to deal with:Losses to follow-upandNon-compliance
appropriately in the analysis
![Page 16: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/16.jpg)
16
Objective 3: Explanatory and pragmatic trials
• Is treatment A better than treatment B?• Two different ways to interpret this
question:
1. Is the physiological action of drug A better than drug B ?
– eg In the treatment for high blood pressure does drug A actually cause a greater fall in blood pressure than drug B ?
![Page 17: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/17.jpg)
17
Is treatment A better than B ?
2. Would the replacement of drug B with drug A benefit patients in routine clinical practice ?
eg Treatment for high blood pressure. If you prescribe A in practice, is A more effective at reducing blood pressure than B ? Will the patients take the drug and will it have the desired effect?
![Page 18: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/18.jpg)
18
Reality of what happens
Randomise
A B
Take Take Don’t take
Don’t take
![Page 19: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/19.jpg)
19
Explanatory trials – ‘as treated’ analysis • Is the physiological action of drug A
better than drug B ?
RandomiseA B
Take Take Don’t take
Don’t take
Ignore those who don’t take the drug
![Page 20: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/20.jpg)
20
Pragmatic (practical) trial – ‘analysis by intention to treat’• In routine clinical practice is A better than
B ?Randomise
A B
Take Take Don’t take Don’t
take
Compare by ‘intention to treat’ – regardless of whether they actually took the treatment!
![Page 21: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/21.jpg)
21
Pragmatic trial – ‘analysis by intention to treat’ -• Comparison ‘by intention to treat’
takes into account factors like the patients don’t like the drugs, forget to take them (doses too frequent) can’t swallow the drugs (too large), there are too many side effects…… and so on……
• If all these are worse in A than B, although at a biological level A might work better than B, in practice A would be less effective than B
![Page 22: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/22.jpg)
22
Example – BP treatment
Treatment group
Number Average blood pressure change
New treatment compliers non-compliers
70 30
-40 mmHg } Overall change +5 mmHg } - 26.5 mmHg
Standard treatment compliers
100
-30 mmHg
![Page 23: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/23.jpg)
23
Objective 4: Why bother with RCTs?
• Why not use historical controls?
– Give new patients the new treatment (A) and for comparison of treatment effect use information about previous patients treated with the old treatment (B)
![Page 24: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/24.jpg)
24
Problems with historical controls
• Old patient selection less well defined• Old patient selection less rigorous• Less information about the controls• Controls may have been treated
differently in other ways, apart from just the difference in the drug
• Control of confounding is poor • The results always over-estimate the
benefits of the new treatment
![Page 25: 1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.](https://reader036.fdocuments.us/reader036/viewer/2022062515/56649ccd5503460f94998164/html5/thumbnails/25.jpg)
25
Summary
1. Suitable outcome measures2. Losses to follow-up & non-
compliance3. Explanatory versus pragmatic trials4. Why historical controls can’t be
used instead of RCTs